Virbac SA (LON:0NM7)

Market Cap	2.47B
Revenue (ttm)	1.16B
Net Income (ttm)	120.15M
Shares Out	n/a
EPS (ttm)	14.34
PE Ratio	20.56
Forward PE	17.13
Dividend	1.24 (0.36%)
Ex-Dividend Date	Jun 24, 2025

Volume	1
Average Volume	1,718
Open	340.50
Previous Close	341.00
Day's Range	339.50 - 342.50
52-Week Range	255.00 - 399.00
Beta	0.84
RSI	64.56
Earnings Date	Sep 12, 2025

About Virbac

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. It serves veterinarians, farmers, and pet owners. The company was founded in 1968 and is headquartered in Carros, France.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1968
• Employees: 6,365
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NM7

Financial Performance

In 2024, Virbac's revenue was 1.40 billion, an increase of 12.07% compared to the previous year's 1.25 billion. Earnings were 145.29 million, an increase of 19.78%.

Financial numbers in EUR